Aligos Therapeutics, Inc. Operating Income
Aligos Therapeutics, Inc. (ALGS) reported Operating Income of -$1.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Aligos Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$1.89M.
- Aligos Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$26.93M.
- Aligos Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$21.81M.
- Aligos Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$28.36M.
- Aligos Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$87.98M.
- Aligos Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$89.15M.
- Aligos Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$88.13M.
- Aligos Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$97.58M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.89M 10-Q · filed 2026-08-06 | -$28.82M 10-Q · filed 2026-08-06 | -$50.63M derived: sum of 3 quarters · filed 2026-08-06 | -$78.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$26.93M 10-Q · filed 2026-05-07 | -$48.74M derived: sum of 2 quarters · filed 2026-05-07 | -$77.10M derived: sum of 3 quarters · filed 2026-05-07 | -$95.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$21.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$50.17M derived: sum of 2 quarters · filed 2026-03-05 | -$68.74M derived: sum of 3 quarters · filed 2026-08-06 | -$87.98M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$28.36M 10-Q · filed 2025-11-06 | -$46.93M derived: sum of 2 quarters · filed 2026-08-06 | -$66.17M 10-Q · filed 2025-11-06 | -$86.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$18.57M 10-Q · filed 2026-08-06 | -$37.81M 10-Q · filed 2026-08-06 | -$58.37M derived: sum of 3 quarters · filed 2026-08-06 | -$78.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$19.24M 10-Q · filed 2026-05-07 | -$39.81M derived: sum of 2 quarters · filed 2026-05-07 | -$59.94M derived: sum of 3 quarters · filed 2026-05-07 | -$86.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$20.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$40.69M derived: sum of 2 quarters · filed 2026-03-05 | -$67.11M derived: sum of 3 quarters · filed 2026-03-05 | -$89.15M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$20.13M 10-Q · filed 2025-11-06 | -$46.55M derived: sum of 2 quarters · filed 2025-11-06 | -$68.59M 10-Q · filed 2025-11-06 | -$94.59M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$26.41M 10-Q · filed 2025-08-06 | -$48.46M 10-Q · filed 2025-08-06 | -$74.46M derived: sum of 3 quarters · filed 2025-08-06 | -$93.53M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$22.05M 10-Q · filed 2025-05-06 | -$48.04M derived: sum of 2 quarters · filed 2025-05-06 | -$67.11M derived: sum of 3 quarters · filed 2025-05-06 | -$86.25M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$45.07M derived: sum of 2 quarters · filed 2025-03-10 | -$64.21M derived: sum of 3 quarters · filed 2025-03-10 | -$88.13M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$19.07M 10-Q · filed 2024-11-06 | -$38.21M derived: sum of 2 quarters · filed 2024-11-06 | -$62.13M 10-Q · filed 2024-11-06 | -$84.81M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$19.14M 10-Q · filed 2024-08-06 | -$43.06M 10-Q · filed 2024-08-06 | -$65.74M derived: sum of 3 quarters · filed 2024-08-06 | -$84.69M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$23.92M 10-Q · filed 2024-05-07 | -$46.60M derived: sum of 2 quarters · filed 2024-05-07 | -$65.55M derived: sum of 3 quarters · filed 2024-05-07 | -$85.94M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$22.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$41.63M derived: sum of 2 quarters · filed 2024-03-12 | -$62.02M derived: sum of 3 quarters · filed 2024-03-12 | -$97.58M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$18.95M 10-Q · filed 2023-11-02 | -$39.34M derived: sum of 2 quarters · filed 2023-11-02 | -$74.90M 10-Q · filed 2023-11-02 | -$112.85M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$20.39M 10-Q · filed 2023-08-03 | -$55.95M 10-Q · filed 2023-08-03 | -$93.90M derived: sum of 3 quarters · filed 2023-08-03 | -$126.97M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$35.56M 10-Q · filed 2023-05-04 | -$73.50M derived: sum of 2 quarters · filed 2023-05-04 | -$106.57M derived: sum of 3 quarters · filed 2023-05-04 | -$136.14M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$37.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$71.02M derived: sum of 2 quarters · filed 2023-03-09 | -$100.58M derived: sum of 3 quarters · filed 2023-03-09 | -$128.32M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$33.07M 10-Q · filed 2022-11-02 | -$62.63M derived: sum of 2 quarters · filed 2022-11-02 | -$90.37M 10-Q · filed 2022-11-02 | -$124.66M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$29.57M 10-Q · filed 2022-08-04 | -$57.30M 10-Q · filed 2022-08-04 | -$91.59M derived: sum of 3 quarters · filed 2022-08-04 | -$113.15M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$27.74M 10-Q · filed 2022-05-04 | -$62.03M derived: sum of 2 quarters · filed 2022-05-04 | -$83.58M derived: sum of 3 quarters · filed 2022-05-04 | -$104.85M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$34.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$55.84M derived: sum of 2 quarters · filed 2022-03-10 | -$77.11M derived: sum of 3 quarters · filed 2022-03-10 | -$97.83M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$21.56M 10-Q · filed 2021-11-04 | -$42.83M derived: sum of 2 quarters · filed 2021-11-04 | -$63.55M 10-Q · filed 2021-11-04 | -$81.98M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$21.27M 10-Q · filed 2021-08-05 | -$41.99M 10-Q · filed 2021-08-05 | -$60.43M derived: sum of 3 quarters · filed 2021-08-05 | -$74.93M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$20.72M 10-Q · filed 2021-05-10 | -$39.16M derived: sum of 2 quarters · filed 2021-05-10 | -$53.66M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$18.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$32.94M derived: sum of 2 quarters · filed 2021-03-23 | -$54.04M 10-K · filed 2021-03-23 | |
| 2019-09-30 | -$14.50M 10-Q · filed 2020-11-25 | -$35.61M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |